
NextCure Investor Relations Material
Latest events

Q2 2025
7 Aug, 2025

Q1 2025
1 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NextCure Inc
Access all reports
NextCure Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomedicines to address cancer and other immune-related diseases by restoring normal immune function. The company's pipeline includes NC410, designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody targeting B7-H4, a protein found on various tumor types; and NC525, which targets LAIR-1 to eliminate AML blast cells and leukemic stem cells while sparing normal blood cells. NextCure's research also extends to preclinical evaluations of additional immunomodulatory molecules. NextCure is headquartered in Beltsville, Maryland, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
NXTC
Country
🇺🇸 United States